Evidence map›Paper›PMID 33851271›Full record

ArticleWorld journal of urology2021

Pattern, timing and predictors of recurrence after surgical resection of chromophobe renal cell carcinoma.

Joana B Neves, Leyre Vanaclocha Saiz, Yasmin Abu-Ghanem, Marta Marchetti, My-Anh Tran-Dang, Soha El-Sheikh, Ravi Barod, Christian Beisland, Umberto Capitanio, David Cullen and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Understanding recurrence in chromophobe RCC.Nature reviews. Urology · 2021
    Article
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 7 institutions in 4 countries.

Joana B Neves *Division of Surgery and Interventional Science, University College London, London, UK.ORCID https://orcid.org/0000-0002-8578-9893
Leyre Vanaclocha Saiz *Faculty of Medical Sciences, University College London, London, UK.ORCID https://orcid.org/0000-0002-7215-2105
Yasmin Abu-GhanemSpecialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Royal Free Hospital, Pond street, London, NW3 2QG, UK.ORCID https://orcid.org/0000-0003-3682-5963
Marta MarchettiSpecialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Royal Free Hospital, Pond street, London, NW3 2QG, UK.
My-Anh Tran-DangDepartment of Pathology, Royal Free London NHS Foundation Trust, London, UK.
Soha El-SheikhDepartment of Pathology, Royal Free London NHS Foundation Trust, London, UK.
Ravi BarodSpecialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Royal Free Hospital, Pond street, London, NW3 2QG, UK.
Christian BeislandDepartment of Clinical Medicine, University of Bergen, Bergen, Norway.ORCID https://orcid.org/0000-0002-3216-4937
Umberto CapitanioDepartment of Urology and Division of Experimental Oncology, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.ORCID https://orcid.org/0000-0001-9225-1795
David CullenSpecialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Royal Free Hospital, Pond street, London, NW3 2QG, UK.
Tobias KlatteDepartment of Urology, Royal Bournemouth Hospital, Bournemouth, UK.ORCID https://orcid.org/0000-0002-4392-6861
Börje LjungbergDepartment of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden.
Faiz MumtazSpecialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Royal Free Hospital, Pond street, London, NW3 2QG, UK.
Prasad PatkiSpecialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Royal Free Hospital, Pond street, London, NW3 2QG, UK.ORCID https://orcid.org/0000-0001-5862-5431
Grant D StewartDepartment of Surgery, University of Cambridge, Cambridge, UK.ORCID https://orcid.org/0000-0003-3188-9140
Saeed Dabestani *Department of Clinical Sciences Lund, Lund University, Skåne University Hospital, Malmö, Sweden.ORCID https://orcid.org/0000-0003-2240-1588
Maxine G B Tran *Division of Surgery and Interventional Science, University College London, London, UK.ORCID https://orcid.org/0000-0002-6034-4433
Axel Bex *Division of Surgery and Interventional Science, University College London, London, UK. axel.bex@nhs.net.
RECUR consortium
Royal Free London NHS Foundation Trust · GBUniversity of Cambridge · GBFaculty (United Kingdom) · GBHaukeland University Hospital · NOIstituti di Ricovero e Cura a Carattere Scientifico · ITLund University · SEUmeå University · SE

Funding

Medical Research Council MR/S00209X/1
6 · The paper itself

Abstract

purposeCurrently there are no specific guidelines for the post-operative follow-up of chromophobe renal cell carcinoma (chRCC). We aimed to evaluate the pattern, location and timing of recurrence after surgery for non-metastatic chRCC and establish predictors of recurrence and cancer-specific death.

methodsRetrospective analysis of consecutive surgically treated non-metastatic chRCC cases from the Royal Free London NHS Foundation Trust (UK, 2015-2019) and the international collaborative database RECUR (15 institutes, 2006-2011). Kaplan-Meier curves were plotted. The association between variables of interest and outcomes were analysed using univariate and multivariate Cox proportional hazards regression models with shared frailty for data source.

results295 patients were identified. Median follow-up was 58 months. The five and ten-year recurrence-free survival rates were 94.3% and 89.2%. Seventeen patients (5.7%) developed recurrent disease, 13 (76.5%) with distant metastases. 54% of metastatic disease diagnoses involved a single organ, most commonly the bone. Early recurrence (< 24 months) was observed in 8 cases, all staged ≥ pT2b. 30 deaths occurred, of which 11 were attributed to chRCC. Sarcomatoid differentiation was rare (n = 4) but associated with recurrence and cancer-specific death on univariate analysis. On multivariate analysis, UICC/AJCC T-stage ≥ pT2b, presence of coagulative necrosis, and positive surgical margins were predictors of recurrence and cancer-specific death.

conclusionRecurrence and death after surgically resected chRCC are rare. For completely excised lesions ≤ pT2a without coagulative necrosis or sarcomatoid features, prognosis is excellent. These patients should be reassured and follow-up intensity curtailed.

Indexed as

AdultAgedAged, 80 and overBone NeoplasmsCarcinoma, Renal CellDisease-Free SurvivalFemaleHumansKaplan-Meier EstimateKidney NeoplasmsMaleMargins of ExcisionMiddle AgedMultivariate AnalysisNecrosisNeoplasm Recurrence, LocalChromophobe renal cell carcinomaFollow-upNephrectomyRenal cell carcinomaSurvival

Identifiers

PMID33851271
OpenAlexW3156350986

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.